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Crizotinib—an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor—is effective in
non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-
positive lung adenocarcinoma who was administered crizotinib via nasogastric and
percutaneous endoscopic gastrostomy (PEG) tubes, with positive results. This case
indicates that patients with ALK-positive NSCLC may successfully be treated with
crizotinib via nasogastric or PEG tubes. This approach can even be used as a salvage
treatment in patients with poor prognoses.
& 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Echinoderm microtubule-associated protein-like 4 (EML4)-
anaplastic lymphoma kinase (ALK) is a fusion-type oncopro-
tein that exists in approximately 5% of non-small cell lung
cancers (NSCLCs) [1–3]. Crizotinib is an orally active, selective
inhibitor of ALK tyrosine kinase that shows promising effects
in the treatment of NSCLCs that harbor EML4-ALK. A phase I
study reported a high overall response rate (57%) against
EML4-ALK-positive advanced NSCLC [4]. In a retrospective
study that compared crizotinib-treated and crizotinib-naivepanese Respiratory Socie
atory Medicine, Kobe City
302 4321.
amai@gmail.com (K. Tamsubsets in a population of EML4-ALK-positive NSCLC patients,
the 1-year and 2-year overall survival rates were 70% and
55%, respectively, in the crizotinib-treated subset, and 44%
and 12%, respectively, in the crizotinib-naive subset [5].
Crizotinib has been added to the National Comprehensive
Cancer Network (NCCN) guideline as a category 2A recom-
mendation for first-line therapy for EML4-ALK-positive
advanced NSCLC [6].
Crizotinib is administered as a capsule taken orally every
day. The major advantage of internal anti-tumor agents is the
ease of administration. Alternative routes of administrationty. Published by Elsevier B.V. All rights reserved.
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been discussed.
To our knowledge, this is the first report of a patient with
poor performance status (PS) being successfully treated with
crizotinib via nasogastric and percutaneous endoscopic gas-
trostomy (PEG) tubes.2. Case report
The patient was a 68-year-old woman without any history of
smoking who was diagnosed with stage T4N3M1a lung
adenocarcinoma in 2009. Genetic analysis revealed no
epidermal growth factor receptor (EGFR) mutations. The
patient therefore underwent 7 rounds of conventional che-
motherapy. However, after the last round of vinorelbine in
2012, the tumor progressed, leading to bilateral recurrent
nerve paralysis and superior vena cava (SVC) syndrome. The
patient also developed dyspnea, for which an emergent
tracheotomy was performed. EML4-ALK expression was sub-
sequently confirmed using both fluorescence in situ hybridi-
zation (FISH) and immunohistochemistry. Crizotinib was
administered orally at a standard dose of 250 mg twice per
day for 18 days after the tracheostomy. Within a week, the
facial edema triggered by SVC syndrome improved. Chest X-
ray showed significant reduction of the primary lesion.
However, the side effects of crizotinib in the digestive system
worsened her PS to 3 and impaired her ability to swallow,
which in turn prevented the use of oral medication. After 7
days of crizotinib treatment, this regimen was discontinued,
and nasogastric feeding was initiated. Over the next 4 days,
the general condition of the patient improved. The attending
staff therefore re-initiated crizotinib treatment at a dose of
250 mg once per day, which was administered via a nasogas-
tric feeding tube from day 12 onward. Percutaneous endo-
scopic gastrostomy (PEG) was performed on day 25 after the
start of treatment; from that point onward, crizotinib was
administered via a gastrostomy tube. The dose of crizotinib
was increased to 200 mg twice per day from the 27th day
onward. Chest X-ray showed significant improvement (Fig. 1).Fig. 1 – (A) A chest X-ray showing the primary lung adenocarcin
the initiation of crizotinib treatment.A chest computed tomography (CT) scan obtained on day 31
revealed a partial response (Fig. 2). The patient was subse-
quently discharged. She continued receiving crizotinib on an
outpatient basis and her PS improved to 1.3. Discussion
To our knowledge, this is the first case report of a patient with
poor PS who was successfully treated with crizotinib.
This case shows that crizotinib can be administered safely
and effectively via nasogastric feeding and PEG tubes for the
treatment of NSCLC patients harboring EML4-ALK.
Crizotinib was administered as a suspension in warm
water at 50 1C. When the patient initially took crizotinib
orally at a dose of 250 mg twice daily, a chest X-ray obtained
at 1 week demonstrated shrinkage of the tumor. When the
drug was administered first via nasogastric tube and then via
PEG tube, even a reduced dose of 250 mg once daily was
effective in reducing tumor size. This approach also alle-
viated the symptoms associated with SVC syndrome and PS.
No complication such as tube obstruction was reported.
The maximum tolerated dose of crizotinib (250 mg twice
daily) was established based on the dose-escalation phase of
an international multicenter phase I trial investigating the
safety, pharmacokinetics, pharmacodynamics, and antitu-
mor activity of crizotinib. The preclinical effective trough
concentration (120 ng/mL) was achieved at doses of Z200 mg
twice daily. Dose-limiting fatigue was observed at doses of
300 mg twice daily [7]. The efficacy of a reduced dose (250 mg
once daily) may reflect the patient’s low body weight (37 kg).
Drug formulation and administration route affect the asso-
ciated pharmacokinetics. For example, Cantarini et al. [8]
reported that administration of the EGFR tyrosine kinase
inhibitor—gefitinib—as a dispersion preparation, orally or by
nasogastric tube, achieved a systemic exposure to gefitinib that
was consistent with that achieved when administered as a
whole tablet. Crizotinib is taken as a capsule, to be swallowed
whole. In the present case, crizotinib was suspended in warm
water at 50 1C and was administered via nasogastric and PEGoma lesion. (B) A chest X-ray obtained on the 24th day after
Fig. 2 – (A) Chest computed tomography (CT) showing enlarged mediastinal lymph nodes, indicating metastasis and the
primary lesion. (B) Chest CT obtained on the 31st day after the initiation of crizotinib treatment.
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concentrations to comprehensively characterize the bioavail-
ability of crizotinib when administered in this fashion.
It has been reported that EGFR mutation-positive patients
with extremely poor PS benefit from treatment with gefitinib
[9]. Chang et al. [10] reported a patient who was under
mechanical ventilation. After 2 weeks of treatment with gefiti-
nib via nasogastric tube, the patient no longer required ventila-
tion assistance. The National Comprehensive Cancer Network
(NCCN) recommends another EGFR tyrosine kinase inhibitor—
elrotinib—as a salvage treatment option for NSCLS patients
with a PS of 4 [6]. Since gefitinib, elrotinib, and crizotinib all
inhibit tyrosine kinase, crizotinib has the potential to benefit
patients with poor PS.
This case supports the contention that patients with
EML4-ALK-positive NSCLC may be treated safely and success-
fully with crizotinib via nasogastric or PEG tubes. This
approach is also effective as a salvage treatment in patients
with poor prognoses.Conflict of interest
The authors have no potential conflicts of interest.
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